



RECEIVED

Sheet 1 of 2

JAN 12 2000

Form 1449*

Atty. Docket No.: 957.001US1

Serial No. 09/345,8

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Applicant: Fatih M. Uckun

TECH CENTER 1600/2900

(Use several sheets if necessary)

Filing Date: June 30, 1999

Group: 1643

U. S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PAR	4,322,420	03/30/1982	Kobayashi et al.	424	251	09/11/79
	4,343,940	08/10/1982	Kreighbaum et al.	544	283	03/06/81
	4,464,375	08/07/1984	Kobayashi et al.	424	251	09/03/81
PAR	5,710,158	01/20/1998	Myers et al.	514	259	04/19/94
	5,792,771	08/11/1998	App et al.	514	259	06/05/95

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
PAR	95/03701	02/09/1995	PCT	A01N	43/04	
	95/15758	06/15/1995	PCT	A61K	31/505	
	96/09294	03/28/1996	PCT	G07D	239/94	
	96/40648	12/19/1996	PCT	G07D	239/74	
PAR	97/03358	01/30/1997	PCT	G01N	33/50	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

PAR	Bridges, A.J., et al., "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor", <u>J. Med. Chem.</u> , 39, pp. 267-276, (1996)
	Budesinsky, Z., et al., "A new synthesis of the quinazoline nucleus", <u>Collection Czechoslov Chem. Commun.</u> , 37 (8), pp. 2779-2785, (1972)
	Fetter, J., et al., "Electron deficient heteroaromatic ammonioamidates-XVI ^a - The synthesis and photochemistry of ethyl N-(2-methyl-4-methylethylene-6,7-methylenedioxy-3,4-dihydro-3-quinazolinyl)-N-phenylcarbamate", <u>Tetrahedron</u> , 34 (16), pp. 2557-2563, (1978)
TV	Goodman, P.A., et al., "Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells", <u>The Journal of Biological Chemistry</u> , 273 (28), pp. 17742-17748, (1998)
PAR	Higashino, T., et al., "Reactions of the anion of quinazoline reissert compound (3-benzoyl-3,4-dihydro-4-quinazolinecarbonitrile) with electrophiles", <u>Chem. Pharm. Bull.</u> , 33 (3), pp. 950-961, (1985)

Examiner

Date Considered

5/23/00

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

Form 1449*

Atty. Docket No.: 957.001US1

Serial No. 09/345,815

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant: Fatih M. Uckun

Filing Date: June 30, 1999

Group: 1643

OTHER DOCUMENTS

**Examiner
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

RAR	Ife R.J., et al., "Reversible inhibitors of the gastric (H ⁺ /K ⁺)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines", <u>J. Med. Chem.</u> , 38, pp. 2763-2773, (1995)
	Kubo, K., et al., "A Novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of pdgf receptor autophosphorylation", <u>Bioorganic & Medicinal Chemistry Letters</u> , 7 (23), pp. 2935-2940, (1997)
	Malaviya, R., et al., "Genetic and Biochemical evidence for a critical role of Janus Kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions", <u>Biochemistry and Biophysical Research Communications</u> , 257 (3), pp. 807-813, (1999)
	Miyashita, A., et al., "An approach to the synthesis of a pavaverine analogue containing a quinazoline ring system", <u>Heterocycles</u> , 40 (2), pp. 653-660, (March 1995)
	Myers, M.R., et al., "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56 ^{lck} adn EGF-R tyrosine kinase activity", <u>Bioorganic & Medicinal Chemistry Letters</u> , 7 (4), pp. 417-420, (1997)
RAR	Narla, R.K., et al., "4-(3'-Bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: A Novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells", <u>Clinical Cancer Research</u> , 4 (6), pp. 1405-1414, (June 1998)

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.